Report

  1. Home
  2. Discounted reports

Antibody Production Market By Product (Instruments, Consumables), By Process (Upstream Processing, Downstream Processing), By End User (Pharmaceutical and Biotechnology Companies, CROs and CDMOs, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Market Report I 2024-03-01 I 276 Pages I Allied Market Research
Discounted by 10% to 2024-11-15

The antibody production market was valued at $12.3billion in 2022 and is projected to reach $29.4billion by 2032, registering a CAGR of 9.1% from 2023 to 2032. Antibody production refers to the process by which specialized cells in the immune system, called B cells, produce antibodies in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Antibodies, also known as immunoglobulins, are Y-shaped proteins that specifically recognize and bind to antigens, which are unique molecules present on the surface of pathogens.
The process of antibody production begins when a B cell encounters an antigen that matches its specific receptor. This encounter triggers the activation and proliferation of the B cell, leading to the production of a large number of identical B cells, known as a clone. These activated B cells then differentiate into plasma cells, which are antibody-producing factories. Plasma cells secrete large quantities of antibodies into the bloodstream and other bodily fluids, where they can bind to and neutralize pathogens or mark them for destruction by other immune cells.
Factors driving the growth of the antibody production market include increase in prevalence of chronic diseases necessitating targeted therapies, advancements in biotechnology enhancing production efficiency and scalability, rising demand for monoclonal antibodies across therapeutic and research applications, and supportive government initiatives fostering research and development in antibody-based therapeutics. In addition, the biopharmaceutical industry is experiencing rapid growth due to increase in investments in research and development, as well as the rise in adoption of biologics-based therapies. Antibodies represent a significant portion of biopharmaceuticals, driving the demand for antibody production technologies and services.
Furthermore, government initiatives aimed at promoting biotechnology research and development, as well as funding support for biopharmaceutical companies and academic institutions, are fostering innovation and growth in the antibody production market. Public-private partnerships and grant programs are also contributing to the expansion of antibody-related research and commercialization efforts. For instance, in 2023, government initiatives for antibody production include the National Institutes of Health (NIH) supporting research to define mechanisms for establishing and maintaining immune responses, such as broadly neutralizing HIV antibodies to protect against HIV acquisition. Thus, rise in government initiatives for research and commercialization of antibodies further propels the market growth.Moreover, monoclonal antibodies (mAbs) have gained widespread acceptance in various therapeutic areas due to their high specificity and efficacy. The increasing number of approved monoclonal antibody drugs and their expanding applications in oncology, immunology, and other fields are driving the demand for antibody production and reagents.
However, the high costs associated with the development and production of antibodies present a significant restraint on the growth of the antibody production market. Antibody development involves a series of complex and resource-intensive processes, including antigen selection, hybridoma or phage display library generation, antibody screening, and optimization. These processes require specialized expertise, sophisticated equipment, and extensive laboratory resources, driving up development costs. Additionally, the production of therapeutic antibodies involves large-scale cell culture, purification, formulation, and quality control steps, all of which contribute to high production costs which may restrain market growth. On the other hand, the growing biopharmaceutical industry, coupled with increase in investments in research and development, presents opportunity to market growth.
The antibody production market is segmented on the basis of product, process, end user and region. By product, the market is bifurcated into instruments and consumables. The instruments segment is further categorized into bioreactors, chromatography systems, and filtration systems. By process, the market is divided into upstream processing and downstream processing. As per end user, it is segregated into pharmaceutical and biotechnology companies, CROs and CDMOs, and others.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the antibody production market are Thermo Fisher Scientific Inc., Sartorius AG, Cellabcdmo, Agilent, Genetix Biotech Asia Pvt. Ltd., Cell Culture Company, Bio-Rad Laboratories, Inc, TECNIC, Merck KGaA, and Danaher Corporation. Key players have adopted acquisition as key developmental strategies to improve the product portfolio of the antibody production market.
Key Benefits for Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody production market analysis from 2022 to 2032 to identify the prevailing antibody production market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the antibody production market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global antibody production market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By End User
- Pharmaceutical and Biotechnology Companies
- CROs and CDMOs
- Others
By Product
- Instruments
- Type
- Bioreactors
- Chromatography Systems
- Filtration Systems
- Consumables
By Process
- Upstream Processing
- Downstream Processing
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Colombia
- Argentina
- Rest Of La
- Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest Of Mea
- Key Market Players
- Thermo Fisher Scientific Inc.
- Sartorius AG
- Cellabcdmo
- Agilent Technologies, Inc.
- Genetix Biotech Asia Pvt. Ltd.
- Cell Culture Company
- Bio-Rad Laboratories, Inc.
- TECNIC
- Merck KGaA
- Danaher Corporation

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Instruments Antibody Production Market by Type
4.3. Consumables
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS
5.1. Overview
5.1.1. Market size and forecast
5.2. Upstream Processing
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Downstream Processing
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical and Biotechnology Companies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. CROs and CDMOs
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Product
7.2.3. Market size and forecast, by Process
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Product
7.2.5.1.2. Market size and forecast, by Process
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Product
7.2.5.2.2. Market size and forecast, by Process
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Product
7.2.5.3.2. Market size and forecast, by Process
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Product
7.3.3. Market size and forecast, by Process
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Product
7.3.5.1.2. Market size and forecast, by Process
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Product
7.3.5.2.2. Market size and forecast, by Process
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Product
7.3.5.3.2. Market size and forecast, by Process
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Product
7.3.5.4.2. Market size and forecast, by Process
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Product
7.3.5.5.2. Market size and forecast, by Process
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Product
7.3.5.6.2. Market size and forecast, by Process
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Product
7.4.3. Market size and forecast, by Process
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Product
7.4.5.1.2. Market size and forecast, by Process
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Product
7.4.5.2.2. Market size and forecast, by Process
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Product
7.4.5.3.2. Market size and forecast, by Process
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Product
7.4.5.4.2. Market size and forecast, by Process
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Product
7.4.5.5.2. Market size and forecast, by Process
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Product
7.4.5.6.2. Market size and forecast, by Process
7.4.5.6.3. Market size and forecast, by End User
7.5. Latin America
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Product
7.5.3. Market size and forecast, by Process
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Product
7.5.5.1.2. Market size and forecast, by Process
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Colombia
7.5.5.2.1. Market size and forecast, by Product
7.5.5.2.2. Market size and forecast, by Process
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. Argentina
7.5.5.3.1. Market size and forecast, by Product
7.5.5.3.2. Market size and forecast, by Process
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest Of La
7.5.5.4.1. Market size and forecast, by Product
7.5.5.4.2. Market size and forecast, by Process
7.5.5.4.3. Market size and forecast, by End User
7.6. Middle East and Africa
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by Product
7.6.3. Market size and forecast, by Process
7.6.4. Market size and forecast, by End User
7.6.5. Market size and forecast, by country
7.6.5.1. Gcc
7.6.5.1.1. Market size and forecast, by Product
7.6.5.1.2. Market size and forecast, by Process
7.6.5.1.3. Market size and forecast, by End User
7.6.5.2. South Africa
7.6.5.2.1. Market size and forecast, by Product
7.6.5.2.2. Market size and forecast, by Process
7.6.5.2.3. Market size and forecast, by End User
7.6.5.3. North Africa
7.6.5.3.1. Market size and forecast, by Product
7.6.5.3.2. Market size and forecast, by Process
7.6.5.3.3. Market size and forecast, by End User
7.6.5.4. Rest Of Mea
7.6.5.4.1. Market size and forecast, by Product
7.6.5.4.2. Market size and forecast, by Process
7.6.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Thermo Fisher Scientific Inc.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Sartorius AG
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Cellabcdmo
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Agilent Technologies, Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Genetix Biotech Asia Pvt. Ltd.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Cell Culture Company
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Bio-Rad Laboratories, Inc.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. TECNIC
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Merck KGaA
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Danaher Corporation
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL INSTRUMENTS ANTIBODY PRODUCTION MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 06. ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
TABLE 07. ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 09. ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ANTIBODY PRODUCTION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTIBODY PRODUCTION MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 18. U.S. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 19. U.S. ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. CANADA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 21. CANADA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 22. CANADA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. MEXICO ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 24. MEXICO ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 25. MEXICO ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 27. EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 28. EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. EUROPE ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 31. GERMANY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 32. GERMANY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. FRANCE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 34. FRANCE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 35. FRANCE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. UK ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 37. UK ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 38. UK ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. ITALY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 40. ITALY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 41. ITALY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. SPAIN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 43. SPAIN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 44. SPAIN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 53. JAPAN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 54. JAPAN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 55. CHINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 56. CHINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 57. CHINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. INDIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 59. INDIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 60. INDIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 71. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 72. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 75. BRAZIL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 79. COLOMBIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 80. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 81. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 82. ARGENTINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. REST OF LA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 84. REST OF LA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 85. REST OF LA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 87. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 88. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 90. GCC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 91. GCC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 92. GCC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 93. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 94. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 95. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 96. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 97. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 98. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 99. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 100. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
TABLE 101. REST OF MEA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 102. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 103. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 104. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 105. THERMO FISHER SCIENTIFIC INC.: SERVICE SEGMENTS
TABLE 106. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 107. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
TABLE 108. SARTORIUS AG: KEY EXECUTIVES
TABLE 109. SARTORIUS AG: COMPANY SNAPSHOT
TABLE 110. SARTORIUS AG: PRODUCT SEGMENTS
TABLE 111. SARTORIUS AG: SERVICE SEGMENTS
TABLE 112. SARTORIUS AG: PRODUCT PORTFOLIO
TABLE 113. SARTORIUS AG: KEY STRATERGIES
TABLE 114. CELLABCDMO: KEY EXECUTIVES
TABLE 115. CELLABCDMO: COMPANY SNAPSHOT
TABLE 116. CELLABCDMO: PRODUCT SEGMENTS
TABLE 117. CELLABCDMO: SERVICE SEGMENTS
TABLE 118. CELLABCDMO: PRODUCT PORTFOLIO
TABLE 119. CELLABCDMO: KEY STRATERGIES
TABLE 120. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 121. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 122. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
TABLE 123. AGILENT TECHNOLOGIES, INC.: SERVICE SEGMENTS
TABLE 124. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 125. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 126. GENETIX BIOTECH ASIA PVT. LTD.: KEY EXECUTIVES
TABLE 127. GENETIX BIOTECH ASIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 128. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT SEGMENTS
TABLE 129. GENETIX BIOTECH ASIA PVT. LTD.: SERVICE SEGMENTS
TABLE 130. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 131. GENETIX BIOTECH ASIA PVT. LTD.: KEY STRATERGIES
TABLE 132. CELL CULTURE COMPANY: KEY EXECUTIVES
TABLE 133. CELL CULTURE COMPANY: COMPANY SNAPSHOT
TABLE 134. CELL CULTURE COMPANY: PRODUCT SEGMENTS
TABLE 135. CELL CULTURE COMPANY: SERVICE SEGMENTS
TABLE 136. CELL CULTURE COMPANY: PRODUCT PORTFOLIO
TABLE 137. CELL CULTURE COMPANY: KEY STRATERGIES
TABLE 138. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
TABLE 139. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 140. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
TABLE 141. BIO-RAD LABORATORIES, INC.: SERVICE SEGMENTS
TABLE 142. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 143. BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
TABLE 144. TECNIC: KEY EXECUTIVES
TABLE 145. TECNIC: COMPANY SNAPSHOT
TABLE 146. TECNIC: PRODUCT SEGMENTS
TABLE 147. TECNIC: SERVICE SEGMENTS
TABLE 148. TECNIC: PRODUCT PORTFOLIO
TABLE 149. TECNIC: KEY STRATERGIES
TABLE 150. MERCK KGAA: KEY EXECUTIVES
TABLE 151. MERCK KGAA: COMPANY SNAPSHOT
TABLE 152. MERCK KGAA: PRODUCT SEGMENTS
TABLE 153. MERCK KGAA: SERVICE SEGMENTS
TABLE 154. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 155. MERCK KGAA: KEY STRATERGIES
TABLE 156. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 157. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 158. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 159. DANAHER CORPORATION: SERVICE SEGMENTS
TABLE 160. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 161. DANAHER CORPORATION: KEY STRATERGIES

LIST OF FIGURES
FIGURE 01. ANTIBODY PRODUCTION MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ANTIBODY PRODUCTION MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN ANTIBODY PRODUCTION MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN ANTIBODY PRODUCTION MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. ANTIBODY PRODUCTION MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. ANTIBODY PRODUCTION MARKET BY REGION, 2022 AND 2032(%)
FIGURE 22. U.S. ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 23. CANADA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 24. MEXICO ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 25. GERMANY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 26. FRANCE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 27. UK ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 28. ITALY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 29. SPAIN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 30. REST OF EUROPE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 31. JAPAN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 32. CHINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 33. INDIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 34. AUSTRALIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 35. SOUTH KOREA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 37. BRAZIL ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 38. COLOMBIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 39. ARGENTINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF LA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 41. GCC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 42. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 43. NORTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF MEA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP: ANTIBODY PRODUCTION MARKET
FIGURE 51. TOP PLAYER POSITIONING, 2022

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3570.00 $3213.00
  • $5730.00 $5157.00
  • $9600.00 $8640.00
  • ADD TO BASKET
  • BUY NOW